Five Prime Therapeutics, Inc (FPRX)

Etorro trading 970x250
Five Prime Therapeutics, Inc (FPRX) Logo

About Five Prime Therapeutics, Inc

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company’s product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors. Its preclinical programs include FPA157, an anti-CCR8 antibody that is engineered to eliminate CCR8-expressing CD4+ regulatory T cells within solid tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, and BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California. Address: 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Five Prime Therapeutics, Inc News and around…

Latest news about Five Prime Therapeutics, Inc (FPRX) common stock and company :

Why Phase 2 Trials Are Important To Investors (And Why I’m Enrolled In One)
06 Apr, 2021 FinancialContent

The biotech sector tends to attract investors who are interested in exciting new medical advances and are drawn to big profits. There are lots of ways to invest in the sector.

8 Retirement Stocks to Buy for Any Market Conditions
06 Apr, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips 2020 shows that investors need to be prepared for anything. These eight retirement stocks can do precisely that. The post 8 Retirement Stocks to Buy for Any Market Conditions appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now

The Secret To Successful Biotech Investing
03 Apr, 2021 FinancialContent

As we advance in years, more people get sick and require more medicines for difficult-to-treat diseases. So if I could invest in only one sector for the next five or ten years, it would be biotech. But how do you choose which ones to invest in?

Is Amgen's Acquisition of Five Prime a Good Move for the Big Biotech?
25 Mar, 2021 FinancialContent

The drugmaker needs as much potential revenue as it can acquire at a reasonable price.

Though Potential Bidders Moved Away, Amgen's Bid For Five Prime Outlasted 15 Suitors
19 Mar, 2021 FinancialContent

Earlier this month, biotech giantAmgen Inc(NASDAQ:AMGN)announced a $1.9 billion buyoutofFive Prime ...

FIVE PRIME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Five Prime Therapeutics - FPRX
11 Mar, 2021 FinancialContent

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Five Prime Therapeutics (NasdaqGS: FPRX) to Amgen (NasdaqGS: AMGN). Under the terms of the proposed transaction, shareholders of Five Prime will receive only $38.00 in cash for each share of Five Prime that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link
10 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Earnings Scheduled For March 10, 2021
10 Mar, 2021 FinancialContent

Companies Reporting Before The Bell • BioDelivery Sciences Intl (NASDAQ:BDSI) is estimated to report quarterly ...

Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call
09 Mar, 2021 FinancialContent

Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

Biotech stocks are a buy — especially these 18 picks
09 Mar, 2021 FinancialContent

The sector's recent pullback offers an chance to get into exciting areas of biotech research like gene editing and oncology at better prices.

Earnings Outlook for Five Prime Therapeutics
09 Mar, 2021 FinancialContent

Five Prime Therapeutics (NASDAQ:FPRX) releases its next round of earnings this Wednesday, March 10. Get the latest predictions in ...

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2021
09 Mar, 2021 FinancialContent

Upgrades ScotiaBank upgraded the previous rating for Primo Water Corp (NYSE:PRMW) from Sector Perform to Outperform. ...

The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings
06 Mar, 2021 FinancialContent

Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, ...

Benzinga's Top Ratings Upgrades, Downgrades For March 5, 2021
05 Mar, 2021 FinancialContent

Upgrades For Boeing Co (NYSE:BA), Canaccord Genuity upgraded the previous rating of Hold to Buy. In the fourth quarter, ...

82 Biggest Movers From Yesterday
05 Mar, 2021 FinancialContent

Gainers Five Prime Therapeutics, Inc. (NASDAQ: FPRX) shares surged 78.7% to close at $38.00 on Thursday after Amgen announced ...

Notable Thursday Option Activity: FPRX, ZM, VECO
04 Mar, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Five Prime Therapeutics, Inc (FPRX), where a total volume of 34,643 contracts has been traded thus far today, a contract volume which is representative of approximately 3.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 413.9% of FPRX's average daily trading volume over the past month, of 836,980 shares..

Mid-Afternoon Market Update: Nasdaq Tumbles Over 200 Points; Five Prime Therapeutics Shares Spike Higher
04 Mar, 2021 FinancialContent

Toward the end of trading Thursday, the Dow traded down 1.07% to 30,935.46 while the NASDAQ fell 1.64% to 12,784.21. The S&P also ...

Amgen to Buy Oncology Start-Up Five Prime Therapeutics for $1.9 Billion
04 Mar, 2021 FinancialContent

The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.

Mid-Day Market Update: Dow Turns Positive; Schrödinger Shares Plummet
04 Mar, 2021 FinancialContent

Midway through trading Thursday, the Dow traded up 0.11% to 31,304.43 while the NASDAQ fell 0.05% to 12,990.83. The S&P also fell, ...

Stocks Mixed Ahead of Powell's Bond Yields Update
04 Mar, 2021 FinancialContent

Better-than-expected jobs data is giving sentiment a lift.

45 Stocks Moving In Thursday's Mid-Day Session
04 Mar, 2021 FinancialContent

Gainers Five Prime Therapeutics, Inc. (NASDAQ: FPRX) shares jumped 78% to $37.85 after Amgen announced plans to acquire the ...

Why Five Prime Therapeutics Stock Is Skyrocketing Today
04 Mar, 2021 FinancialContent

Amgen is paying a premium to buy the small biotech.

FPRX Stock: The Huge Takeover News That Has Five Prime Therapeutics Shares Blasting Higher
04 Mar, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Five Prime Therapeutics (FPRX) stock is soaring higher on Thursday following news that Amgen (AMGN) is acquiring the company. The post FPRX Stock: The Huge Takeover News That Has Five Prime Therapeutics Shares Blasting Higher appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now

Amgen Pays $1.9B For Five Prime Therapeutics Acquisition
04 Mar, 2021 FinancialContent

Amgen Inc(NASDAQ:AMGN)has agreed to acquireFive Prime Therapeutics Inc(NASDAQ:FPRX) for $38 per ...

Five Prime Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Five Prime Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm –
04 Mar, 2021 FinancialContent

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) to Amgen Inc. for $38.00 per share in cash is fair to Five Prime shareholders.

Mid-Morning Market Update: Markets Open Lower; Kroger Posts Mixed Q4 Results
04 Mar, 2021 FinancialContent

Following the market opening Thursday, the Dow traded down 0.22% to 31,202.42 while the NASDAQ fell 1.6% to 12,790.20. The S&P also ...

Five Prime Therapeutics Stock Rockets On Amgen's $1.9 Billion Takeover
04 Mar, 2021 FinancialContent

Amgen said Thursday it will spend $1.9 billion to buy Five Prime Therapeutics, a small biotech company with a promising stomach cancer drug. The news sent FPRX stock rocketing.

Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash
04 Mar, 2021 FinancialContent

AMGEN TO ACQUIRE FIVE PRIME THERAPEUTICS FOR $1.9 BILLION IN CASH

Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call
02 Mar, 2021 FinancialContent

Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call

Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference
26 Feb, 2021 FinancialContent

Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference

Five Prime Therapeutics, Inc (FPRX) is a NASDAQ Common Stock listed in , ,

970x250